GlassScriptPhysician profile
John Arthur Honch
NPI 1134121460
$6,121.95
in general payments reported to CMS, 2019-2025
33 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $443 · 2021: $782 · 2022: $981 · 2023: $1,034 · 2024: $1,157 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,237 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,237.09 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,766.12 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $861.37 | 2020-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $785.20 | 2020-2025 | Absorica Ld, Winlevi, Blu-U |
| Lilly USA, LLC | $440.46 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $343.70 | 2021-2025 | |
| Galderma Laboratories, L.P. | $254.72 | 2019-2025 | Nemluvio |
| Pfizer INC. | $223.87 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $193.55 | 2019-2022 | |
| Leo Pharma INC. | $190.10 | 2019-2025 | Anzupgo, Adbry |
| Incyte Corporation | $114.50 | 2021-2024 | Opzelura |
| Amgen INC. | $106.84 | 2021-2025 | Otezla |
| Epi Health, LLC | $97.98 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $80.17 | 2020-2021 | |
| Almirall LLC | $78.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $71.79 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $64.06 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.27 | 2019 | |
| Biofrontera INC. | $46.91 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $41.12 | 2024-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $37.01 | 2020 | |
| Dusa Pharmaceuticals, INC. | $35.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.14 | 2025 | Sotyktu |
| Organon LLC | $26.83 | 2025 | Vtama |
| Dermira, INC. | $26.41 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $23.87 | 2019 | |
| Botanix Sb INC | $21.03 | 2025 | Sofdra |
| Ucb, INC. | $17.83 | 2021 | |
| Phadia US INC. | $16.16 | 2023 | Immunocap |
| Icad, INC | $15.77 | 2022 | |
| Sandoz INC. | $15.21 | 2020 | |
| Medline Industries LP | $14.50 | 2025 | |
| Aclaris Therapeutics, INC. | $13.55 | 2019 | |
| Journey Medical Corporation | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Honch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.